National webinars and special eventsBack to previous page
php echo wp_list_categories(); ?>
PSA is excited to offer a national webinar series available to all members across Australia.
The one hour monthly webinar will enable you to interactively engage and question the expert speakers in real time from anywhere in Australia.
Multiple choice questions will be available online to enable you to gain Group 2 Credits for each webinar.
Webinars will be recorded and accessible to view a few days after the live webinar via the PSA Online Learning listing.
How we prevent and manage HIV has come a long way since its discovery over 30 years ago. HIV medicine has advanced to the point where the elimination of all HIV transmission is achievable in the short-term and has been implemented as a key strategic goal by a number of Australian state governments.
Critical to this success is the population-based, targeted roll-out of HIV PrEP. PrEP involves taking one pill daily of tenofovir disoproxil fumarate (TDF)/ emtricitabine (FTC), available in Australia as Truvada. TDF/FTC has been extensively used in millions of people with HIV for about 15 years, and with international data suggesting a 99% reduction in risk of contracting HIV when used daily in HIV negative people, the introduction of PrEP is redefining our thoughts and beliefs around safer sex practices.
To help achieve this goal, it is paramount that community, hospital and consultant pharmacists have the confidence, skills and knowledge to provide comprehensive care when managing patients using PrEP or requesting information about its indication and availability.
This lecture aims to empower pharmacists to have a greater understanding of the pharmacology of nucleoside reverse transcriptase inhibitors (NRTIs), their therapeutic use and efficacy in HIV prevention when used as PrEP, results from ongoing research, accessibility avenues and the counselling points for educating and managing patients using PrEP or accessing information about it.
ACT, NSW, QLD, TAS & VIC – 7.30pm
SA & NT – 7pm
WA – 5.30pm
Upon completion of this activity, pharmacist should be able to:
- Describe the pharmacology of nucleoside reverse transcriptase inhibitors (NRITs)
- Explain NRTIs therapeutic use and efficacy in HIV prevention when used as PrEP
- Summarise the key results from PrEP studies
- Recognise the importance of educating and managing patients using PrEP or those wanting to access information about PrEP
This event addresses the following competency standards (2010): 1.3.2, 1.4.2, 4.2.1, 4.2.2, 4.2.3, 4.3.3, 6.1.1, 6.1.3, 6.2.2, 6.3.1, 6.3.2, 6.3.3, 8.1.3, 8.2.3.
This information is correct at the time of publication and subject to change.
This lecture is currently undergoing accreditation.
Associate Professor Iryna Zablotska-Manos PhD, MD, MPH
The Kirby Institute, UNSW.
Iryna Zablotska-Manos is a Senior Lecturer with the Kirby Institute, Faculty of Medicine, UNSW. She is an epidemiologist with primary interest in behavioural risk factors and prevention of HIV and STIs. During her research career, she worked on sexual behaviour and behavioural surveillance for HIV and STIs, reproductive health, and evaluation of public health and health communication programs.
She is currently a lead investigator on the EPIC-NSW (Expanded PrEP Implementation in Communities) trial – a study run by the Kirby Institute and funded by the NSW Government, in collaboration with a number of partners such as sexual health services and clinics. EPIC-NSW aims to assess the impact of the rapid expansion in access to HIV pre-exposure prophylaxis (PrEP) amongst those at highest risk of acquiring HIV, in particular, if it will lead to a drop in new HIV infections.
Supported by Gilead. Gilead has had no input into the content of the materials and presentation used at this event.
This item is listed in the following categories: • Branch events